71 |
Estudo da sinalização por GMP cíclico em Blastocladiella emersonii / Studies in cyclic GMP signaling pathway in Blastocladiella emersoniiGabriela Mól Avelar Tamaki 10 December 2014 (has links)
O segundo mensageiro cGMP está envolvido em diversas funções celulares incluindo a visão em mamíferos. Embora trabalhos anteriores mostrassem variações nos níveis de cGMP durante o ciclo de vida de Blastocladiela emersonii e evidências da existência de enzimas específicas envolvidas na sua síntese (guanilato ciclase) e degradação (cGMP fosfodiesterase), nenhum genoma de fungo publicado até o momento mostrou a existência de genes codificando estas enzimas. Este fato é atribuído por evolucionistas à completa perda de motilidade dos fungos em geral, já que cGMP está primordialmente associado a células com cílios. Blastocladiomicetos, como Blastocladiella, apresentam células móveis em pelo menos um estágio do seu ciclo de vida, o que poderia explicar a existência dessa via nesses fungos. Uma investigação no banco de ESTs de B. emersonii revelou a existência de cDNAs codificando parte de prováveis guanilato ciclases (BeGC1, BeGC2 e BeGC3) e uma possível cGMP fosfodiesterase (BePDE). Assim, este trabalho buscou confirmar a existência destas enzimas e caracterizar a sinalização por cGMP em B. emersonii. A proteína recombinante selvagem correspondente ao domínio catalítico de BePDE mostrou atividade de degradação sobre cGMP e a mutação E389A foi capaz de alterar a especificidade por cGMP. Com o sequênciamento do genoma de B. emersonii obteve-se as sequências completas das guanilato ciclases. Em BeGC2 não foi possível identificar o ligante responsável por sua ativação. Em BeGC3, a presença de um domínio Heme-Pas sugeriu sua ativação por óxido nítrico. A presença de um domínio rodopsina em BeGC1 sugeriu sua ativação por luz. Experimentos de microscopia por imunofluorescência localizaram BeGC1 no \"eyespot\", BeGC2 no capacete nuclear e BeGC3 no citoplasma de zoósporos de B. emersonii. Verificamos também que zoósporos realizam fototaxia em direção à luz verde e que a adição de hidroxilamina, inibidor de rodopsina, ou do inibidor de guanilato ciclase LY83583 tem efeito negativo na fototaxia, bem como impede o aumento dos níveis de cGMP observado em zoósporos expostos à luz verde. O bloqueio da síntese de retinal por Norflurazon também inibiu a fototaxia sendo esta restaurada quando adicionamos retinalA1. Estes dados, juntamente com o fato de o domínio rodopsina de BeGC1 ser a única rodopsina presente no genoma, indicam que BeGC1 é responsável pela fototaxia nos zoósporos de B. emersonii. O genoma do fungo apresenta ainda um possível canal de potássio ativado por cGMP (BeCNG1) localizado na membrana plasmática de zoósporos, similar ao canal regulado por cGMP envolvido na visão em humanos. Ensaios de microfluorimetria também evidenciaram a presença de um canal ativado por cGMP relacionado com o influxo de potássio e a motilidade dos zoósporos. Um modelo para a via de sinalização da fototaxia em B.emersonii foi proposto e comparado com a sinalização presente na visão de mamíferos, destacando a existência de cGMP e rodopsina em ambos os processos e sugerindo uma possível origem comum. Portanto, os resultados obtidos suportam a existência da sinalização por cGMP em B. emersonii, além de indicar o papel dessa sinalização na fototaxia dos zoósporos, sendo esta a primeira via de sinalização por cGMP caracterizada em fungos. / The second messenger cyclic GMP is involved in a wide array of cellular processes including vision in mammals. Although previous studies demonstrated changes in cGMP levels during the life cycle of Blastocladiela emersonii and evidences of specific enzymes involved in its synthesis (guanylyl cyclase) and hydrolysis (cGMP-phosphodiesterase), no fungal genome published so far shows the presence of genes encoding these enzymes. Evolutionists attribute the absence of cGMP signaling pathways in higher fungi to the sedentary life style of these organisms, since cGMP is primarily associated with ciliated cells. However, blastocladiomycetes like Blastocladiella, have motile cells in at least one stage of their life cycle, which could explain the existence of this pathway in these primitive fungi. Inspection of B. emersonii EST data bank, revealed cDNAs encoding part of three putative guanylyl cyclases (BeGC1, BeGC2 e BeGC3) and one possible cGMP phosphodiesterase (BePDE). Thus, the purpose of this study was to confirm the existence of these enzymes and characterize the cGMP signaling pathway in this model. The recombinant protein containing the wild type catalytic domain of BePDE presented activity towards hydrolysis of cGMP and the E389A mutation of this domain changed the cGMP specificity of this enzyme. The complete nucleotide sequence of the guanylyl cyclases were obtained by sequencing of B. emersonii genome. In BeGC2 we were unable identify the ligand responsible for its activation, but in BeGC3, the presence of a Heme-Pas domain suggested its activation by nitric oxide. The presence of a rhodopsin domain in BeGC1 suggested its activation by light. Immunofluorescence microscopy localized BeGC1 in the \"eyespot\" structure, BeGC2 in the nuclear cap and BeGC3 in the cytoplasm of zoospores of B. emersonii. We found that Blastocladiella zoospores performed phototaxis toward green light and photobleaching of rhodopsin function using hydroxylamine prevented both phototaxis and the increased cGMP levels observed when zoospores were exposed to green light. The same effect was observed using the guanylyl cyclase inhibitor LY83583. Inhibition of retinal synthesis using Norflurazon prevented the phototaxis response, which could be restored by zoospore complementation with retinalA1. The BeGC1 gene is the only rhodopsin found in the draft assembly of B. emersonii genome, which indicates that BeGC1 is responsible for phototaxis observed in zoospores. We also found in the genome a possible cGMP-activated potassium channel (BeCNG1), localized in the plasma membrane of the zoospores, which is similar to the cGMP-activated channel involved in human vision. In addition, microfluorimetry assays revealed the presence of a cGMP-activated potassium channel involved in potassium influx and zoospore motility. The signaling model of B. emersonii phototaxis was proposed and compared with the mammalian vision system, with cGMP and rhodopsin acting in both signaling pathways, suggesting a common origin. Altogether our data indicate that Blastocladiella emersonii has a cGMP signaling system involved in phototaxis, being the first cGMP signaling pathway characterized in fungi.
|
72 |
Maturation modulates both synthesis and degradation of cGMP in ovine vascular smooth muscleWhite, Charles Ray 01 January 1994 (has links)
No description available.
|
73 |
L'activation de la phosphodiestérase de type 2 pour traiter l'insuffisance cardiaque / Activation of phosphodiesterase type 2 to treat heart failureLindner, Marta 12 October 2016 (has links)
L’AMP cyclique (AMPc) et le GMP cyclique (GMPc) sont des seconds messagers essentiels pour la régulation de la fonction cardiaque. La concentration de l’AMPc intracellulaire est régulée par les activités d'au moins deux familles d'enzymes: les cyclases et guanylyl cyclases, responsable de la synthèse de l'AMPc et du GMPc, et les phosphodiestérases (PDE) qui interviennent dans l’hydrolyse de l'AMPc et du GMPc.Parmi la superfamille des PDEs, la PDE2 est une enzyme à double substrat qui hydrolyse à la fois l'AMPc et le GMPc et a la propriété unique d'être stimulée par le GMPc. Il a été récemment montré que la PDE2 du myocarde est augmentée dans l'insuffisance cardiaque humaine et expérimentale (IC), tandis que d'autres (par exemple PDE3 et PDE4) sont réduites. Cependant, les conséquences physiopathologiques de l'activité PDE2 renforcée dans le cœur sont inconnues.Dans ce contexte, nous avons généré des souris transgénique (TG) avec une surexpression spécifique cardiaque de l’isoforme PDE2A3 (souris PDE2 TG).Grace à l’utilisation de Western blot et de dosage radioenzymatique nous avons montré que l'AMPc cardiaque et l'activité PDE cGMP et l'activité spécifique de PDE2 sont fortement augmentées dans les PDE2 TG par rapport à des souris de type sauvage (WT).Le raccourcissement cellulaire, les transitoires calciques et le courant calcique de type L (ICa, L) ont été enregistrés dans les myocytes ventriculaires adultes de souris WT et PDE2 TG et l'isoprénaline (ISO) a été utilisée pour examiner et comparer la réponse β-adrénergique (β-AR) de ces paramètres. Nous avons montré que lors de la stimulation β-AR, la contractilité cellulaire, la transitoire Ca2+ et l’amplitude du courant ICa,L sont fortement diminués. En conséquence, la surexpression de la PDE2 dans les cardiomyocytes a réduit les taux d'AMPc et abolit l'effet inotrope après une stimulation β-AR aiguë. L'ECG mesuré par télémétrie chez la souris PDE2 TG a montré une réduction marquée de la fréquence cardiaque au repos ainsi que de la fréquence cardiaque maximale, tandis que le débit cardiaque a est entièrement préservé en raison d'une contractilité plus forte. Fait important, les souris TG PDE2 sont résistantes à des arythmies ventriculaires déclenchées et à des arythmies induites par isoprénaline.En conclusion, ce travail montre que PDE2 joue un rôle essentiel dans la régulation du couplage excitation-contraction cardiaque. La surexpression de PDE2 semble protéger les cardiomyocytes contre une stimulation excessive β-AR et réduit le risque d'arythmie lors de l'activation sympathique.L’activation de la PDE2 peut donc représenter une nouvelle stratégie thérapeutique anti-adrénergique et anti-arythmique subcellulaire dans l’insuffisance cardiaque. / Cyclic AMP (cAMP) and cyclic GMP (cGMP) are critical second messengers for the regulation of cardiac function. Intracellular cAMP concentration is regulated by the activities of at least two families of enzymes: adenylyl and guanylyl cyclases, responsible for cAMP and cGMP synthesis and cyclic nucleotide phosphodiesterases (PDEs) that mediate cAMP and cGMP hydrolysis.Among the PDE superfamily, PDE2 is a dual substrate enzyme that hydrolyzes both cAMP and cGMP and has the unique property to be stimulated by cGMP. It was recently showed that myocardial PDE2 is increased in human and experimental heart failure (HF), while other PDEs (e.g. PDE3 and PDE4) are reduced. However, the pathophysiological consequences of enhanced PDE2 activity in the heart are unknown.In this context, we generated a transgenic (TG) mouse with a heart specific overexpression of the PDE2A3 isoform (PDE2 TG mouse). Using immunoblotting and radioenzymatic assay we showed that total cardiac cAMP and cGMP PDE activity and specific PDE2 activity was strongly increased in PDE2 TG compared to wild type (WT) mice. Sarcomere shortening, Ca2+ transients and the whole L-type Ca2+ current (ICa,L) were recorded in adult ventricular myocytes from WT and PDE2 TG mice and isoprenaline (ISO) was used to examine and compare the β-adrenergic (β-AR) response of these parameters. We showed that upon β-AR stimulation, cell contractility, Ca2+ transient and ICa,L were severely blunted. Accordingly, PDE2 overexpression in cardiomyocytes reduced the cAMP levels and abolished the inotropic effect following acute β-AR stimulation. ECG telemetry in PDE2 TG mice showed a marked reduction in resting as well as in maximal heart rate, while cardiac output was completely preserved due to greater contractility. Importantly, PDE2 TG mice were resistant to triggered ventricular arrhythmias and to isoprenaline-induced arrhythmias.In conclusion, this work demonstrates that PDE2 plays a critical role in the regulation of cardiac excitation-contraction coupling. PDE2 overexpression appears to protect the cardiomyocytes against excessive β-AR drive and reduces the risk of arrhythmias during sympathetic activation. PDE2 activation may thus represent a new subcellular anti-adrenergic and anti-arrhythmic therapeutic strategy in HF.
|
74 |
Régulation différentielle de l’activité PKA cytoplasmique et nucléaire par les récepteurs β1- et β2-ARs dans les cardiomyocytes ventriculaires de rat adulte / Differential regulation of cytoplasmic and nuclear PKA activity by β1- and β2-ARs in adult rat ventricular myocytesBedioune, Ibrahim 06 October 2017 (has links)
Dans le cœur, l’activation aiguë de la voie AMPc/PKA via la stimulation des récepteurs β-adrénergiques (β-ARs) permet de réguler la contraction cardiaque alors que l’activation chronique de cette voie est délétère, car elle est source de survenue d’arythmies cardiaques et de remodelage hypertrophique du cœur. Au niveau des cardiomyocytes, Il existe principalement deux sous-types de récepteurs β-ARs ; β1- et β2-ARs, qui exercent des effets différents sur la fonction cardiaque.Dans une première partie de ma thèse, je me suis intéressé à l’étude du rôle des récepteurs β1- et β2-ARs dans la régulation différentielle de l’activité PKA cytoplasmique et nucléaire. J’ai ainsi pu montrer que contrairement aux récepteurs β1-ARs qui ont la capacité d’activer la PKA au niveau du cytoplasme et aux noyaux, les récepteurs β2-ARs activent la PKA uniquement au niveau du cytoplasme, et ce indépendamment de la capacité des récepteurs β2-ARs à induire une augmentation des niveaux d’AMPc dans les noyaux. En accord avec ces résultats, les récepteurs β1- mais pas β2-ARs activent le facteur pro-apoptotique régulé par la PKA, ICER.Dans une seconde partie de ma thèse, je me suis intéressé aux différents mécanismes responsables de l’incapacité des récepteurs β2-ARs à activer la PKA au niveau des noyaux. Mes résultats soulignent le rôle de la localisation des récepteurs β2-ARs au niveau des cavéoles, leurs couplage aux protéines Gi, leurs désensibilisation par la GRK2 ainsi que la dégradation de l’AMPc généré par ces récepteurs par la PDE3 et 4 dans la régulation de la signalisation PKA cytoplasmique et pointent vers la PDE4 comme un régulateur central permettant de limiter l’activation de la PKA holoenzyme responsable des réponses PKA nucléaires. Mes résultats montrent également que la mAKAP est un élément clé dans la transduction de la signalisation PKA nucléaire induite par les récepteurs β2-ARs et à un moindre degré, les récepteurs β1-ARs. Dans la dernière partie de ma thèse, j’ai étudié le remodelage de la signalisation PKA nucléaire induite par les récepteurs β1- et β2-ARs au cours de l’insuffisance cardiaque. J’ai ainsi pu montrer qu’en plus de la diminution de la signalisation PKA nucléaire induite par les récepteurs β1-ARs, il existe une signalisation PKA nucléaire de novo induite par les récepteurs β2-ARs dans les cardiomyocytes de rat adulte insuffisants.En conclusion, ce travail a mis à jour une nouvelle différence entre les récepteurs β1- et β2-ARs dans la signalisation PKA au niveau des noyaux des cardiomyocytes de rat adultes, et souligne le rôle important de la PDE4 et de la mAKAP dans la régulation de la signalisation PKA nucléaire induite par les récepteurs β2-ARs. / In the heart, acute activation of the cAMP/PKA pathway upon stimulation of β-adrenoceptors (β-ARs), plays a fundamental role in the regulation of cardiac function, whereas chronic activation of this pathway is deleterious, as it is responsible for cardiac arrhythmias and hypertrophic remodeling of the heart. In cardiac myocytes, there are mainly two subtypes of β-ARs: β1- and β2-ARs, which exert different effects on cardiac function.In the first part of my thesis, my work was focused on understanding the role of β1- and β2-ARs in the differential regulation of cytoplasmic and nuclear PKA activity. Hence, I have showed that unlike β1-ARs which have the capacity to induce the activation of PKA in the cytoplasm and the nucleus, β2-ARs induce the activation of PKA only in the cytoplasmic compartment, regardless of their ability to induce an increase in cAMP in the nuclei. Consistently, β1- but not β2-ARs were able to induce the activation of the pro-apoptotic factor regulated by PKA, ICER.The second aim of my thesis was to decipher the different mechanisms involved in the inability of β2-ARs to activate PKA in the nucleus. I concentrated my efforts on investigating the role of the localization of β2-ARs in caveolae, their coupling to Gi proteins, their desensitization by GRK2 as well as the hydrolysis of cAMP by PDE3 and 4 in the regulation of β2-AR-induced cytoplasmic PKA activity. My results point to PDE4 as a central regulator which limits the activation of the PKA holoenzyme pool involved in the nuclear PKA responses. My results also show that mAKAP is a key component of nuclear PKA signaling induced by β2-ARs and to a lesser extent by β1-ARs. In the last part of my thesis, I have studied the remodeling of nuclear PKA signaling induced by β1- and β2-ARs that occurs during heart failure. I showed that, besides a decrease in β1-AR-induced nuclear PKA signaling, there is a de novo β2-AR-induced nuclear PKA signaling in cardiomyocytes from rat with heart failure.In conclusion, this work uncovers a new difference in PKA signaling between β1- and β2-ARs at the nuclear compartment of adult rat cardiomyocytes and underlines the importance of PDE4 and mAKAP in the regulation of β2-AR-induced nuclear PKA signaling.
|
75 |
Kinetická analýza enzymové aktivity modelových hemových senzorových proteinů / Enzyme activity analysis of function domains belonging to model heme-containing sensor proteinsProšková, Veronika January 2018 (has links)
EN This Ph.D. thesis focuses on the heme containing gas sensor proteins. These proteins are predominantly present in bacteria, in which play an important role in processes like, sporulation, antibiotic resistance and so on. Heme containing sensor proteins composed of two domains. First one is a globin domain, which contains the heme molecule. Interaction of heme with gas molecule acts as a signal for the activation/inactivation of the second functional domain. Part of this thesis is formed by a review, which summarized the current knowledge about heme containing sensor proteins. In the next part of this thesis we focused on three representatives from the group of oxygen sensor proteins - histidine kinase AfGcHK, diguanylate cyclase YddV and phosphodiesterase EcDOS. The main aim of this thesis was to solve the mechanism of interdomain/intraprotein signal transduction in two oxygen sensor proteins with globin fold of their sensor domain (AfGcHK, YddV). For this purpose, we used the kinetic analysis of their functional domain activity and the methods of structural biology. We also studied the mechanism of interprotein signal transduction in AfGcHK and its cognate partner RR protein. It was also tested, how the presence of sodium disulfide affects the functional properties of oxygen sensor proteins...
|
76 |
Thérapie génique de l'insuffisance cardiaque par les phosphodiestérases / Gene therapy of heart failure with phosphodiesterasesBourcier, Aurélia 24 October 2019 (has links)
Une stimulation β-adrénergique (β-AR) aigue, par exemple au cours d’un exercice physique, accroît le second messager AMPc dans les cardiomyocytes aboutissant à une cascade d’évènements permettant d’augmenter la fonction cardiaque. Une élévation chronique des taux de catécholamines est délétère puisqu’elle participe au remodelage pathologique du cœur et à la progression vers l’insuffisance cardiaque (IC). L'IC correspond à l'incapacité du cœur à répondre aux besoins hémodynamiques de l'organisme. Si la majorité des patients meurt de défaillance cardiaque, une part importante décède d'arythmies.Les phosphodiestérases (PDEs) sont des enzymes essentielles puisqu’elles permettent non seulement la terminaison des signaux AMPc en dégradant ce nucléotide cyclique en 5’AMP inactif mais aussi l’organisation spatiale de ces signaux dans des compartiments subcellulaires spécifiques. L'IC s'accompagne de profonds remaniements de la voie β-AR et l'expression des PDEs est modifiée en conditions pathologiques, perturbant ainsi la compartimentation intracellulaire de l’AMPc. Il a été notamment démontré que l’expression d’une isoforme de PDE particulière, la PDE4B, diminue dans l'hypertrophie cardiaque et que l’invalidation du gène codant pour celle-ci favorise les arythmies ventriculaires chez la souris lors d’une stimulation β-AR. À l’inverse, l'expression d'une autre enzyme, la PDE2A, est augmentée dans l’IC, chez l’homme et différents modèles animaux. Ceci constituerait un mécanisme de défense lors d'un stress cardiaque puisqu’il a été montré que sa surexpression atténue l’hypertrophie induite par la noradrénaline ou la phényléphrine et limite les arythmies chez la souris.L’objectif de mon travail était de tester l’hypothèse qu’une augmentation de l’activité des PDEs pourrait constituer une alternative aux traitements classiques de l’IC, pour limiter le remodelage hypertrophique, la progression vers l’IC et les arythmies associées. Pour cela, j’ai réalisé une thérapie génique dans des modèles murins d'IC grâce à des virus adéno-associé de type 9 (AAV9) codant pour la PDE4B ou la PDE2A. Mes résultats suggèrent que cette approche pourrait constituer une nouvelle stratégie thérapeutique prometteuse de l'IC en limitant le dysfonctionnement cardiaque, l’hypertrophie du ventricule gauche, et la survenue des arythmies ventriculaires mais seulement lorsque la PDE2A est surexprimée. / Acute stimulation of β-adrenergic receptors (β-ARs), for example during physical activity, leads to the synthesis of the second messenger cAMP in cardiomyocytes, which triggers a cascade of events leading to the increase of cardiac function. While acute β-AR stimulation is beneficial to the heart, chronic β-AR activation is detrimental because it promotes cardiac remodeling and ultimately leads to heart failure (HF). HF is defined by the heart's inability to overcome hemodynamic needs of the body. While the majority of patients die of worsening heart function, a significant proportion dies suddenly of cardiac arrhythmias.Phosphodiesterases (PDEs) are crucial enzymes since they allow not only to terminate cAMP signals by degrading this second messenger into inactive 5’AMP but permit their spatial organization in subcellular compartments. HF is accompanied by profound rearrangements of the β-AR pathway and the expression of PDEs is modified under pathological conditions, thus disrupting cAMP intracellular compartmentation. The expression of one of these enzymes, PDE4B, is decreased in cardiac hypertrophy and the invalidation of the gene encoding PDE4B promotes ventricular arrhythmias under β-AR stimulation in mice. Conversely, the expression of another enzyme, PDE2A, is up-regulated in human and animal models of HF which may constitute an important defense mechanism during cardiac stress since its overexpression attenuates hypertrophy induced by norepinephrine or phenylephrine and limits cardiac arrhythmias.The purpose of my work was to test the hypothesis that an increase of PDE activity could constitute an alternative to conventional HF treatments to limit cardiac remodeling, HF progression and associated arrhythmias. To do so, I performed a cardiac gene therapy in mouse models of HF using serotype 9 adeno-associated viruses (AAV9) encoding for PDE4B or PDE2A. My results suggest that this approach may be a promising new therapeutic strategy during HF by limiting cardiac dysfunction, left ventricular hypertrophy, and could protect ventricular arrhythmias only when PDE2A is overexpressed.
|
77 |
Roles of acid sphingomyelinase in HDL-cholesterol metabolism : lessons from Niemann-Pick disease type ILee, Karen Ching Yin, 1978- January 2007 (has links)
No description available.
|
78 |
Expression, Cloning, and Sequencing of Putative Insulin Signaling Genes Involved in Diapause in the Flesh Fly <em>Sarcophaga crassipalpis</em>.Barker, Andrew Bellamy 16 August 2005 (has links) (PDF)
Diapause is a programmed developmental arrest that allows insects to survive harsh environmental conditions. The diapause state has been linked to the insulin signaling pathway. Insulin signaling has been associated with many physiological processes including aging. It is a working hypothesis that the diapause and aging programs have a common set of gene expression pathways via insulin signaling. Analysis of a heterologous microarray indicated that two genes involved in the insulin pathway were down regulated during diapause. Both of these genes, Pi3K68d and Pde6, along with the Insulin receptor (InR) were targets for further investigation. Putative gene products have been isolated, cloned, and sequenced. RNA interference experimentation was conducted to characterize the role of the putative InR gene products obtained.
|
79 |
Einfluss der Phosphodiesterase 10A auf cAMP-abhängige Signalwege und deren Effekt auf osteogene Differenzierung und Mechanotransduktion von mesenchymalen Stromazellen / Influence of phosphodiesterase 10A on cAMP-dependent signaling pathways and their effect on osteogenic differentiation and mechanotransduction of mesenchymal stromal cellsEge, Carolin January 2023 (has links) (PDF)
Humane mesenchymale Stromazellen sind in der Lage in osteogene Zellen zu differenzieren, und für diese osteogene Differenzierung ist mechanische Belastung ein relevanter Kostimulus. Mechanotransduktion hat zur Folge, dass second messenger wie cAMP und cGMP gebildet werden und sich die Ca2+-Konzentration erhöht, welche wiederum Transkriptionsfaktoren aktivieren, die die Regulation von Genen osteogener Marker vermitteln. Die second messenger cAMP und cGMP werden abgebaut durch Phosphodiesterasen, jedoch ist die Rolle dieser Phosphodiesterasen während der osteogenen Differenzierung oder Mechanotransduktion weiterhin unklar.
Das Ziel dieser Arbeit war es, herauszufinden, inwieweit im Besonderen die Phosphodiesterase 10A einen Einfluss nimmt auf die osteogene Differenzierung und die Mechanotransduktion von mesenchymalen Stromazellen und inwiefern sie dabei die cAMP-abhängigen Signalwege moduliert. Langfristig soll hiermit herausgefunden wer-den, welche Bedeutung die PDE10A auf altersinduzierte Krankheiten hat, wobei der Fokus zunächst auf der Osteoporose liegen soll.
Um dies zu erreichen, wurden experimentelle Versuche zunächst mit HEK293- und hMSC-TERT-Zellen als Modell für mesenchymale Stromazellen durchgeführt, dann auch mit den mesenchymalen Stromazellen selbst. Untersucht wurde der Einfluss des PDE10A-Inhibitors Papaverin auf die Zellen und auf deren mechanische Induzierbarkeit, sowieso auf die osteogene Differenzierung der hMSC. Außerdem wurden weitere mechanische Versuche durchgeführt, zur Überprüfung des Effekts der Phosphodiesterase 10A.
Es wurde beobachtet, dass die Inhibierung von PDE10A mit Papaverin die osteogene Differenzierung und Mineralisierung vermindert. Außerdem gab es einen ersten Hinweis, dass eine Überexpression von PDE10A schwächenden Einfluss nimmt auf die Expression mechanoresponsiver Gene.
Nachfolgend auf diese Arbeit wurde erkannt, dass die Expression von mechanoresponsiven Genen durch die PDE10A-Inhibition unterdrückt wird. / Human mesenchymal stromal cells are able to differentiate into osteogenic cells, and for this osteogenic differentiation mechanical stress is a relevant costimulus. Mechanotransduction results in the formation of second messengers such as cAMP and cGMP and an increase in Ca2+ concentration, which in turn activate transcription factors that mediate the regulation of osteogenic marker genes. The second messengers cAMP and cGMP are degraded by phosphodiesterases, but the role of these phosphodiesterases during osteogenic differentiation or mechanotransduction remains unclear.
The aim of this work was to determine to what extent phosphodiesterase 10A in particular influences osteogenic differentiation and mechanotransduction of mesenchymal stromal cells and to what extent it modulates cAMP-dependent signaling pathways. In the long term, the aim is to find out what role PDE10A plays in age-related diseases, with an initial focus on osteoporosis.
To achieve this, experimental trials were first performed using HEK293 and hMSC-TERT cells as a model for mesenchymal stromal cells, and then also using the mesenchymal stromal cells themselves. The influence of the PDE10A inhibitor papaverine on the cells and on their mechanical inducibility, as well as on the osteogenic differentiation of hMSC was investigated. In addition, further mechanical experiments were performed, to verify the effect of phosphodiesterase 10A.
It was observed that inhibition of PDE10A with papaverine decreased osteogenic differentiation and mineralization. In addition, there was initial evidence that overexpression of PDE10A has a debilitating effect on the expression of mechanoresponsive genes.
Subsequent to this work, it was recognized that the expression of mechanoresponsive genes is suppressed by PDE10A inhibition.
|
80 |
MODULATION OF CYCLIC ADENOSINE MONOPHOSPHATE FOR POTENTIATION OF LONG-ACTING β2-AGONIST AND GLUCOCORTICOIDS IN HUMAN AIRWAY EPITHELIAL CELLSKim, Yechan January 2019 (has links)
McMaster University MASTER OF SCIENCE (2019) Hamilton, Ontario (Medical Sciences)
TITLE: Modulation of cyclic adenosine monophosphate for potentiation of long-acting β2-agonist and glucocorticoids in human airway epithelial cells AUTHOR: Yechan Kim, B.HSc. (McMaster University) SUPERVISOR: Dr. Jeremy Alexander Hirota NUMBER OF PAGES: xiv, 81 / In Canada, asthma is the third most common chronic disease resulting in 250 premature deaths annually and related healthcare expenses exceeding $2.1 billion/year. It is estimated that around 50-80% of asthma exacerbations are due to viral infections. Despite an advanced understanding on how to treat and manage the symptoms of asthma, current therapy is sub-optimal in 35-50% of moderate-severe asthmatics around the world resulting in lung inflammation, persistent impairment of lung function, and increased risk of mortality. Combination of long-acting β2 agonists (LABA) for bronchodilation and glucocorticoids (GCS) to control lung inflammation represent the dominant strategy for the management of asthma. Increasing intracellular cyclic adenosine monophosphate (cAMP) beyond existing combination LABA/GCS are likely to be beneficial for the management of difficult to control asthmatics that are hypo-responsive to mainstay therapy. In human airway epithelial cells (HAEC), cAMP is either exported by transporters or broken down by enzymes, such as phosphodiesterase 4 (PDE4). We have demonstrated that HAEC express ATP Binding Cassette Transporter C4 (ABCC4), an extracellular cAMP transporter. We also show that ABCC4 and PDE4 inhibition can potentiate LABA/GCS anti-inflammatory responses in a human epithelial cell line in a cAMP-dependent mechanism validating the pursuit of novel ABCC4 inhibitors as a cAMP elevating agent for asthma. / Thesis / Master of Science in Medical Sciences (MSMS) / Asthma is a common chronic lung disease characterized by narrow and inflamed airways that cause breathing difficulties. Current management includes the combination of bronchodilators, to relax the airway, and steroids, to decrease inflammation. Unfortunately, this combination therapy is suboptimal in 35-50% of users, increasing the risk of asthma attacks, hospitalization rate, and health care costs. Recently, there have been studies theorizing that we can improve the therapy’s ability to decrease inflammation by increasing cAMP, an important molecule for biological activities. We tested this claim by blocking the breakdown and export of cAMP to increase its levels and measured inflammatory cytokines, molecules that direct the action of immune cells. Our results show that in a model of viral infection, administering the combination therapy while increasing cAMP levels can further decrease inflammatory cytokines prompting further investigation for its potential implication in the clinic.
|
Page generated in 0.0914 seconds